Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein

Clinical and Translational Imaging

Volumn 3, Issue 6, 2015, Pages 449-460

  van der Doef, Thalia F ^a,b   Doorduin, Janine ^c   van Berckel, Bart N M ^a,b   Cervenka, Simon ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Microglia; Neuroinflammation; PET; Psychiatry; TSPO

Indexed keywords

18 KDA TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

DEPRESSION; DEVELOPMENTAL DISORDER; FUNCTIONAL NEUROIMAGING; HUMAN; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNE SYSTEM; MENTAL DISEASE; MICROGLIA; MOLECULAR IMAGING; MOOD DISORDER; NERVOUS SYSTEM INFLAMMATION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SUBSTANCE USE; TREATMENT OUTCOME;

EID: 84952993593     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-015-0140-0     Document Type: Review

References (100)

1. Oommen KJ, Johnson PC, Ray CG (1982) Herpes simplex type 2 virus encephalitis presenting as psychosis. Am J Med 73:445–448
2. Felgenhauer K (1990) Psychiatric disorders in the encephalitic form of multiple sclerosis. J Neurol 237:11–18
3. Reichenberg A, Yirmiya R, Schuld A et al (2001) Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58:445–452
4. Dantzer R, O’Connor JC, Freund GG et al (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56
5. Mednick SA, Machon RA, Huttunen MO, Bonnet D (1988) Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 45:189
6. Arias I, Sorlozano A, Villegas E et al (2012) Infectious agents associated with schizophrenia: a meta-analysis. Schizophr Res 136:128–136
7. Benros ME, Waltoft BL, Nordentoft M et al (2013) Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 70:812–820
8. Ripke S, Neale BM, Corvin A et al (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421–427
9. Odell D, Maciulis A, Cutler A et al (2005) Confirmation of the association of the C4B null allelle in autism. Hum Immunol 66:140–145
10. Consortium N and PAS of PG (2015) Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 18:199–209
11. Laan W, Selten J-P, Grobbee DE et al (2007) Non-steroidal anti-inflammatory drugs and the risk of psychosis. Eur Neuropsychopharmacol 17:309–311
12. Radewicz K, Garey LJ, Gentleman SM, Reynolds R (2000) Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59:137–150
13. Kreisl WC, Jenko KJ, Hines CS et al (2013) A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 33:53–58
14. Morgan JT, Chana G, Pardo CA et al (2010) Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 68:368–376
15. Little KY, Ramssen E, Welchko R et al (2009) Decreased brain dopamine cell numbers in human cocaine users. Psychiatry Res 168:173–180
16. Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155:101–108
17. Miller BJ, Buckley P, Seabolt W et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671
18. Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457
19. Mitchell RHB, Goldstein BI (2014) Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. J Am Acad Child Adolesc Psychiatry 53:274–296
20. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC et al (2010) Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 13:1369–1381
21. Bromander S, Anckarsäter R, Kristiansson M et al (2012) Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study. J Neuroinflammation 9:242
22. Maier B, Laurer H-L, Rose S et al (2005) Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma 22:822–835
23. Soderlund J, Schroder J, Nordin C et al (2009) Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 14:1069–1071
24. Schwieler L, Larsson MK, Skogh E et al (2014) Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia—significance for activation of the kynurenine pathway. J Psychiatry Neurosci 39:140126
25. Jakobsson J, Bjerke M, Sahebi S et al (2015) Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci 40:250–258
26. Söderlund J, Olsson SK, Samuelsson M et al (2011) Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci 36:114–118
27. Young JJ, Bruno D, Pomara N (2014) A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord 169C:15–20
28. Rahmim A, Zaidi H (2008) PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 29:193–207
29. Liu G-J, Middleton RJ, Hatty CR et al (2014) The 18 kDa translocator protein, microglia and neuroinflammation. Brain Pathol 24:631–653
30. Venneti S, Lopresti BJ, Wiley CA (2013) Molecular imaging of microglia/macrophages in the brain. Glia 61:10–23
31. Hohlfeld R, Kerschensteiner M, Meinl E (2007) Dual role of inflammation in CNS disease. Neurology 68:S58–S63 (discussion S91–6)
32. Paolicelli RC, Gross CT (2011) Microglia in development: linking brain wiring to brain environment. Neuron Glia Biol 7:77–83
33. Cagnin A, Gerhard A, Banati RB (2002) In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol 12:581–586
34. Gerhard A, Schwarz J, Myers R et al (2005) Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage 24:591–595
35. Fujita M, Imaizumi M, Zoghbi S, Fujimura Y (2008) Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for. Neuroimage 40:43–52
36. Imaizumi M, Briard E, Zoghbi S, Gourley J (2008) Brain and whole-body imaging in nonhuman primates of PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage 39:1289–1298
37. Ikoma Y, Yasuno F, Ito H et al (2007) Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. J Cereb Blood Flow Metab 27:173–184
38. Maeda J, Suhara T, Zhang M-R et al (2004) Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse 52:283–291
39. Rusjan PM, Wilson AA, Bloomfield PM et al (2011) Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab 31:1807–1816
40. Wilson AA, Garcia A, Parkes J et al (2008) Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol 35:305–314
41. Kreisl WC, Fujita M, Fujimura Y et al (2010) Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 49:2924–2932
42. Owen DRJ, Gunn RN, Rabiner EA et al (2011) Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 52:24–32
43. Van Berckel BN, Bossong MG, Boellaard R et al (2008) Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 64:820–822
44. Doorduin J, de Vries EFJ, Willemsen ATM et al (2009) Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 50:1801–1807
45. Takano A, Arakawa R, Ito H et al (2010) Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 13:943–950
46. Kenk M, Selvanathan T, Rao N et al (2014) Imaging neuroinflammation in gray and white matter in schizophrenia: an in vivo PET study with [18F]-FEPPA. Schizophr Bull 41:85–93
47. Gavish M, Bachman I, Shoukrun R et al (1999) Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 51:629–650
48. Kalk NJ, Owen DR, Tyacke RJ et al (2013) Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies? Synapse 67:909–912
49. Danovich L, Veenman L, Leschiner S et al (2008) The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur Neuropsychopharmacol 18:24–33
50. Hannestad J, Della Gioia N, Gallezot JD et al (2013) The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C]PBR28 PET study. Brain Behav Immun 33:131–138
51. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389
52. Ichise M, Toyama H, Innis RB et al (2002) Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22:1271–1281
53. Setiawan E, Wilson AA, Mizrahi R et al (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72:268–275
54. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
55. Haarman BCMB, Riemersma-Van der Lek RF, de Groot JC et al (2014) Neuroinflammation in bipolar disorder: a [11C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun 40:219–225
56. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186
57. Haarman BBCM, Riemersma-Van der Lek RF, Burger H et al (2014) Relationship between clinical features and inflammation-related monocyte gene expression in bipolar disorder—towards a better understanding of psychoimmunological interactions. Bipolar Disord 16:137–150
58. Rybakowski JK (2000) Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry 33:159–164
59. Suzuki K, Sugihara G, Ouchi Y et al (2013) Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 70:49–58
60. Sekine Y, Ouchi Y, Sugihara G et al (2008) Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28:5756–5761
61. Narendran R, Lopresti BJ, Mason NS et al (2014) Cocaine abuse in humans is not associated with increased microglial activation: an 18-kDa translocator protein positron emission tomography imaging study with [11C]PBR28. J Neurosci 34:9945–9950
62. Ziedonis D, Hitsman B, Beckham JC et al (2008) Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 10:1691–1715
63. Bally N, Zullino D, Aubry JM (2014) Cannabis use and first manic episode. J Affect Disord 165:103–108
64. Leweke FM, Koethe D (2008) Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 13:264–275
65. Guan Y-Z, Jin X-D, Guan L-X et al (2014) Nicotine inhibits microglial proliferation and is neuroprotective in global ischemia rats. Mol Neurobiol 51:1480–1488
66. Suárez-Pinilla P, López-Gil J, Crespo-Facorro B (2014) Immune system: a possible nexus between cannabinoids and psychosis. Brain Behav Immun 40:269–282
67. Van der Staay FJ, Arndt SS, Nordquist RE (2009) Evaluation of animal models of neurobehavioral disorders. Behav Brain Funct 5:11
68. Mattei D, Djodari-Irani A, Hadar R et al (2014) Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain Behav Immun 38:175–184
69. Juckel G, Manitz MP, Brüne M et al (2011) Microglial activation in a neuroinflammational animal model of schizophrenia: a pilot study. Schizophr Res 131:96–100
70. Fu X, Zunich SM, O’Connor JC et al (2010) Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation 7:43
71. O’Connor JC, Lawson MA, André C et al (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14:511–522
72. Buttini M, Limonta S, Boddeke HWGM (1996) Peripheral administration of lipopolysaccharide induces activation of microglial cells in rat brain. Neurochem Int 29:25–35
73. Reader BF, Jarrett BL, McKim DB et al (2015) Peripheral and central effects of repeated social defeat stress: monocyte trafficking, microglial activation, and anxiety. Neuroscience 289:429–442
74. Doorduin J, Klein HC, Dierckx RAJO, de Vries EFJ (2010) HSV-1 induced behavioural changes and microglia cell activation are inhibited by antipsychotics. Eur J Nucl Med Mol Imaging 37:S387
75. Dobos N, De Vries EFJ, Kema IP et al (2012) The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimer’s Dis 28:905–915
76. Hannestad J, Gallezot JD, Schafbauer T et al (2012) Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates. Neuroimage 63:232–239
77. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158
78. Logan J (2000) Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 27:661–670
79. Lyoo CH, Ikawa M, Liow JS et al (2015) Cerebellum can serve as a pseudo-reference region in Alzheimer’s disease to detect neuroinflammation with PET radioligand binding to translocator protein (TSPO). J Nucl Med 56:701–706
80. Schuitemaker A, van der Doef TF, Boellaard R et al (2012) Microglial activation in healthy aging. Neurobiol Aging 33:1067–1072
81. Owen DR, Guo Q, Kalk NJ et al (2014) Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study. J Cereb Blood Flow Metab 34:989–994
82. Folkersma H, Boellaard R, Yaqub M et al (2011) Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med 52:1235–1239
83. Su Z, Herholz K, Gerhard A et al (2013) [11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur J Nucl Med Mol Imaging 40:1406–1419
84. Schain M, Benjaminsson S, Varnäs K et al (2013) Arterial input function derived from pairwise correlations between PET-image voxels. J Cereb Blood Flow Metab 33:1058–1065
85. Kanegawa N, Schain M, Collste K et al (2015) Towards less invasive quantification of [11C]PBR28: image-derived and population-based input functions. XIIth: International Conference on Quantification of Brain Function with PET, Vancouver, June 27–30 2015. http://iscbfm.org/Meetings.aspx
86. Bilbo SD, Schwarz JM (2009) Early-life programming of later-life brain and behavior: a critical role for the immune system. Front Behav Neurosci 3:14
87. Jučaite A, Cselényi Z, Arvidsson A et al (2012) Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain: a PET study in control subjects. EJNMMI Res 2:15
88. Park E, Gallezot J-D, Delgadillo A et al (2015) 11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging 42:1081–1092
89. Collste K, Forsberg A, Varrone A et al (2015) Test-retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging [Epub ahead of print]
90. Lavisse S, Guillermier M, Herard A-S et al (2012) Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 32:10809–10818
91. Tóth M, Little P, Arnberg F et al (2015) Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: longitudinal positron emission tomography and immunofluorescent tracking. Brain Struct Funct [Epub ahead of print]
92. Asadabadi M, Mohammadi M-R, Ghanizadeh A et al (2013) Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 225:51–59
93. Sommer IE, de Witte L, Begemann M, Kahn RS (2012) Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 73:414–419
94. Abbasi S-H, Hosseini F, Modabbernia A et al (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 141:308–314
95. Nitta M, Kishimoto T, Müller N et al (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 39:1230–1241
96. Oya K, Kishi T, Iwata N (2014) Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 29:483–491
97. Laan W, Grobbee DE, Selten J-P et al (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:520–527
98. Jucaite A, Svenningsson P, Rinne JO et al (2015) Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease. Brain 138:2687–2700
99. Deakin J, Lennox BR, Zandi MS (2014) Antibodies to the N-methyl-d-aspartate receptor and other synaptic proteins in psychosis. Biol Psychiatry 75:284–291
100. Raison CL (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41